What's Happening?
CHO Plus has been awarded a project agreement from the Biomedical Advanced Research and Development Authority’s (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium for up to $10.4 million. This funding is aimed at developing high productivity Chinese hamster ovary (CHO) cell lines to manufacture filovirus monoclonal antibodies over a 30-month period. Additionally, CHO Plus has partnered with Avid Bioservices to scale up monoclonal antibody production. The company was also selected for the 2025 BioTools Innovator Accelerator, joining 31 startups in a program that offers mentorship, investor exposure, and networking opportunities.
AD
Why It's Important?
The project agreement with BARDA positions CHO Plus as a key player in the development of therapeutic monoclonal antibodies, which are crucial in combating highly contagious and lethal filoviruses. The partnership with Avid Bioservices for scaling production indicates a move towards industrial-scale manufacturing, potentially enhancing the availability of these critical biologics. Participation in the BioTools Innovator Accelerator provides CHO Plus with valuable resources and exposure, which could accelerate the commercialization of its high-productivity cell lines, impacting the biologics production industry.
What's Next?
CHO Plus will focus on advancing its cell line development and scaling up production capabilities in collaboration with Avid Bioservices. The company will also engage in the BioTools Innovator Accelerator program, leveraging mentorship and networking opportunities to further its growth and innovation in biologics production. The potential success in the accelerator program could lead to additional funding and partnerships, enhancing CHO Plus's market position and technological advancements.
